ORIGINAL RESEARCH article

Front. Immunol., 11 July 2023

Sec. Viral Immunology

Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1198530

Association between laboratory markers and Covid-19 disease severity and outcome: a retrospective cohort study in Saudi Arabia

  • 1. Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

  • 2. Regenerative Medicine Unit, King Fahad Medical Research Center, King Abdulaziz Univeristy, Jeddah, Saudi Arabia

  • 3. Diagnostic Virology, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia

  • 4. Computer Science Department, Faculty of Computing and Information Technology, King Abdulaziz University, Jeddah, Saudi Arabia

  • 5. Center for Artificial Intelligence in Precision Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

  • 6. King Abdulaziz and his Companions Foundation for Giftedness and Creativity “Mawhiba”, King Abdulaziz University, Jeddah, Saudi Arabia

  • 7. Restorative Dentistry Department, Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia

  • 8. Conservative Dentistry Department, Faculty of Dentistry, October University for Modern Sciences and Arts University, Cairo, Egypt

  • 9. Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

  • 10. Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

  • 11. Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Article metrics

View details

2

Citations

2k

Views

731

Downloads

Abstract

Introduction:

In Saudi Arabia, limited studies have evaluated factors including epidemiologic, clinical, and laboratory findings that are associated with COVID-19 disease. The aim of this paper was to identify laboratory parameters used in King Abdulaziz University Hospital which show an association with disease severity and patient outcome in the form of mortality.

Methods:

Age, gender, medical history, and laboratory parameters were all retrospectively assessed concerning disease severity and disease outcome in a total of 111 COVID-19 patients at King Abdulaziz University Hospital between July 2020 and August 2020. Patients were categorized into mild disease if they did not require ward admission, moderate if they met the Ministry of Health criteria for isolation ward admition, and severe if they were admitted to the ICU.

Results:

Age but not gender was associated with the disease severity X2 (4, N = 110) = 27.2, p <0.001. Of all laboratory parameters on admission, only the levels of Albumin appeared to be significantly associated X2 (2, N =70) = 6.6, p <0.05 with disease severity. Age but not gender was also significantly associated with disease outcome X2 (2, N = 110) = 12.8, p < 0.01. Interestingly, RBC count also showed a significant relation with disease outcome X2 (2, N = 71) = 6.1, p <0.05.

Discussion:

This study provides more understanding of the laboratory characteristics in our part of the world to efficiently manage the disease.

Introduction

In 2020, Corona Virus disease (COVID-19) was declared as a global pandemic by the World Health Organization (WHO) (1, 2). Up to October 2022, WHO reported a global total number of 623,000,396 confirmed cases including 6,550,033 deaths by the disease (3). Saudi Arabia was no exception, and like many other countries has undergone serious health threats with the pandemic. Up to October 2022, there have been 819,323 confirmed cases of COVID-19 with 9,384 deaths in Saudi Arabia reported to WHO (3). By October 2022, the 7-day average number of new cases was 191 (3). Such numbers confirm WHO’s perspectives that “…the COVID-19 pandemic remains an acute global emergency” and the risk for new variants and future surges remains a real threat.

Since the beginning of the pandemic, the disease exhibited a very variable presentation following an unforeseeable course, making it hard to predict disease outcomes in individuals (4, 5). A large number of infected patients were asymptomatic, while others showed a wide spectrum of symptoms and signs ranging from fever, cough, fatigue, shortness of breath in mild illness, to severe life threatening pneumonia and critical disease in the form of respiratory failure and multi- organ dysfunction. The disease is characterized by cytokine storm and coagulation abnormalities which ultimately can result in tissue destruction and vital organs dysfunction (4).

Similar to many countries world-wide, the pandemic exhibited a huge strain on Saudi Arabia’s healthcare system. A study conducted to assess hospital and ICU bed surge capacity during the pandemic concluded that there was an urgent need for hospital and ICU beds to accommodate critical cases in Saudi Arabia (6). Decisions thus related to postponing admission and discharging patients from wards are crucial and require critical assessment in addition to reliable predictors that can predict disease severity (6).

Previous studies have investigated the relationship of blood/serum biomarkers with disease severity and disease outcomes. High neutrophil count, lymphopenia, high C-reactive protein (CRP), Lactate dehydrogenase (LDH), Ferritin, and IL-6, for example, were all shown to be predictors of disease severity in various studies world-wide. In Saudi Arabia, however, very limited studies have evaluated effective indicators which correlated with the disease including epidemiologic, clinical, and laboratory findings. In a retrospective study conducted at King Abdulla Hospital in Bisha province between March 20 and June 30 2022, a high LDL level and neutrophil count and low lymphocyte count was found in all patients (7). In addition, a significant association was seen between cardiovascular diseases, hypertension, renal failure, old age, and death from the disease. In another study, conducted in four private tertiary hospitals and one private hospital in Riyadh, aspartate aminotransferase (AST), CRP, D-dimer, and ferritin were all significantly higher in moderate cases in comparison to mild cases (8). It is worth noting however that those factors were assessed during the first three months of the pandemic which showed special circumstances in terms of mandating hospital isolation, admission criteria, and management plans.

King Abdulaziz University Hospital (KAUH) in Jeddah is one of the largest educational hospitals in Saudi Arabia with a very multi-cultural patient population and played an essential role in accommodating COVID-19 cases. The aim of this paper was to define the laboratory markers used in KAUH that showed an association with disease severity, and patient outcome in the form of mortality during the period between July 2020 and August 2020.

Materials and methods

Study population and data collection

This study was a retrospective study conducted at KAUH in Jeddah, Saudi Arabia and approved by the Biomedical Research Ethics Committee ethics board at King Abdul-Aziz University (Reference No 360-20).

The study included all COVID-19 patients, confirmed by nasopharyngeal swab RT-PCR for SARS-CoV-2, admitted between July 2020 and August 2020, which was a total of 151 patients. Excluded were pediatric patients, pregnant women, and those who did not have any electronic medical records, leading to a total inclusion of 111 patients. Patients were categorized into Mild, Moderate and Severe disease. Mild disease if they did not require ward admission, which was equivalent to categories 1 and 2 according to the WHO ordinal clinical severity scale i.e ambulatory without activity limitation or with activity limitation. Moderate if they were admitted to the isolation ward which was equivalent to categories 3,4 and 5 on the WHO scale. Severe if they were admitted to the ICU which was equivalent to categories 6,7 and 8. Confirmed cases were admitted to the isolation ward if they met the Ministry of Health SCDC guideline criteria, which included patients who were symptomatic and showed signs of severe disease such as low oxygen saturation SpO2<94% on room air, hemodynamic instability, clinical or radiographic evidence of pneumonia. In addition, patients who were at risk of severe disease such as co-morbidities and immunocompromised patients, especially if they showed signs of active cytokine release, were admitted. Patients who showed deterioration clinically and were not able to main oxygen saturation with non-invasive methods of oxygenation were admitted to ICU.

A standard laboratory workup was done for all confirmed COVID-19 patients which ensured that all routine laboratory tests were requested for all patients and at standardized time points during their admission.

A predesigned form was designed to collect data from patients’ electronic medical records. Data included age, gender, past medical history, length of hospital stay, patient outcome which was defined as recovery if patients was discharged or death in cases of in-hospital mortality, COVID-19 complications which included new events (unrelated to previous medical history) of pneumonia, organ failure, cardiac problems, blood clots and acute kidney injury, in addition to all the laboratory parameters ordered for patients.

Statistical analysis

Data analysis was conducted using SPSS version 25. Descriptive data were described as frequency (N) and percentage. Shapiro-Wilk test was used to check if continuous variables follow a normal distribution. Mann-Whitney U test and Kruskal-Wallis test were used when comparing two or more than two groups, respectively. For further analysis and to facilitate application of statistical and machine learning models in future work, continuous data was transferred to categorical data (low, normal, high). The chi-squared test for independence was used to test the association between the categories. Dependent study variables were defined as a binary outcome. A Binary Logistic Regression Model (BLRM), with Enter Criteria=0.05 and Elimination=0.10 was used to determine the significant predictors of any given dependent study variables with 95% confidence intervals. A General Linear Model (GLM) univariate analysis was also used to identify significant predictors using Main Effect as model. A P-value less than 0.05 was considered statistically significant.

Results

Descriptive data of COVID-19 cases is presented in Table 1. Overall, the majority of cases were mild cases that required only an ER visit without admission (41.4%), while 39.6% of cases were moderate which were ward-admitted, and 18.9% were severe cases that required ICU admission. 88.3% of the cases recovered during their hospital stay and were discharged in stable condition, while the remaining 11.7% were inpatient mortality cases. Hospital stay was less than 7 days in 65.7% of cases, and the majority of patients (70.3%) did not develop any COVID-19-related complication.

Table 1

Frequency(N) Percent (%)
Severity
  Mild 46 41.4
 Moderate  44 39.6
 Severe 21 18.9
 Total 111 100.0
Complication
 No complication 78 70.3
 Complication 33 29.7
 Total 111 100.0
Outcomes
 Recovery 98 88.3
 Inpatient mortality 13 11.7
 Total 111 100.0
Hospital stay
 < 7 days 73 65.7
 ≥ 7 days 38 34.2
 Total 111 100.0
History of Medical disease
 No medical condition 63 56.8
 Medical condition 48 43.2
 Total 111 100.0
Gender
 Male 67 60.4
 Female 44 39.6
Age
 18-44 50 45.0
 45-64 42 37.8
 ≥ 65 18 16.2

Descriptive data of COVID-19 cases.

In terms of the laboratory parameters measured upon admission (including ER admission), most patients fell in the normal range of most parameters except for lymphocyte, monocyte and eosinophil count, D-dimer, ferritin, Albumin, AST, and LDH levels (Table 2). 86.3%,45.1%, and 82.2% of all patients showed low lymphocyte, monocyte and eosinophil count, respectively. 62.7% of patients showed high D-dimer levels and 74.1% had high ferritin levels. Albumin levels were low in 68.6% of patients, while AST and LDH levels were high in 57.1% and 84.7% of patients respectively.

Table 2

Parameter Frequency (N) Percent (%)
Hgb Low 27 36.9
Normal 44 60.3
High 2 2.7
Total 73 100.0
RBC count Low 34 46.6
Normal 36 49.3
High 3 4.1
Total 73 100.0
PLT Low 13 17.8
Normal 56 76.7
High 4 5.5
Total 73 100.0
WBC Low 18 24.6
Normal 45 61.6
High 10 13.8
Total 73 100
Neutrophils Low 11 15.1
Normal 45 61.6
High 17 23.3
Total 73 100.0
*Lymphocytes Low 63 86.3
Normal 10 13.7
Total 73 100
*Monocytes Low 32 45.1
Normal 30 42.3
High 9 12.6
Total 71 100
*Eosinophils Low 60 82.2
Normal 10 13.7
High 3 4.1
Total 73 100
Basophils Low 8 11
Normal 60 82.2
High 5 6.8
Total 73 100
*D-Dimer Normal 22 37.3
High 37 62.7
Total 59 100
PT Normal 50 79.4
High 13 20.6
Total 63 100
APTT Normal 57 92
High 5 8
Total 62 100
INR Normal 50 79.4
High 13 20.6
Total 63 100
*Ferritin Normal 15 25.9
High 43 74.1
Total 58 100
Na Low 33 45.2
Normal 40 54.8
Total 73 100
K Low 13 17.8
Normal 53 72.6
High 7 9.6
Total 73 100
Cl Low 9 12.3
Normal 64 87.7
Total 73 100
Urea Low 7 9.6
Normal 42 57.5
High 24 32.9
Total 73 100
Creatinine Low 12 16.7
Normal 43 59.7
High 17 23.6
Total 72 100
Total protein Low 4 5.7
Normal 59 84.3
High 7 10
Total 70 100
*Albumin Low 48 68.6
Normal 22 31.4
Total 70 100
ALP Normal 65 91.5
High 6 8.5
Total 71 100
*AST Low 3 4.3
Normal 27 38.6
High 40 57.1
Total 70 100
ALT Normal 54 76.1
High 17 23.9
Total 71 100
GTT Normal 47 66.2
High 24 33.8
Total 71 100
Total Bilirubin Normal 64 90.1
High 7 9.9
Total 71 100
*LDH Normal 9 15.3
High 50 84.7
Total 59 100

Laboratory parameter ranges in admitted patients.

*Indicate paramters in which the majority of patients (bold) fell either higher or lower than normal range.

In order to study the relationship between the various parameters and COVID-19 severity, a chi-square test of independence was performed to look for significant association between each category and disease severity (Table 3). Developing a COVID-19-related complication, and disease outcome (recovery or inpatient mortality) was, as expected, associated with disease severity X2 (2, N = 111) = 69.2, p <0.001 and X2 (2, N = 111) = 63.1, p <0.001, respectively. History of a previous medical condition was also associated with disease severity X2 (2, N = 111) = 48.7, p <0.001. Age but not gender was associated with the disease severity X2 (4, N = 110) = 27.2, p <0.001. There was a significant difference between patients ≥65 and patients between 45-64 compared to patients between 18-44 (p<0.0001, p<0.001 respectively) in terms of disease severity, with the former groups showing more severe disease. However, no significant difference in disease severity was found between patients ≥65 and patients between 45-64. Interestingly, out of all the laboratory parameters on admission, only the levels of Albumin appeared to be significantly associated X2 (2, N =70) = 6.6, p =0.036 with disease severity, however, it is worth mentioning that ALT levels reached a p-value of 0.059, X2 (2, N =71)=5.6. To further confirm the association between the parameters and disease severity an ANOVA analysis was done for each of the significant parameters. We found that severe cases showed a significantly higher level of ferritin when compared to moderate (p<0.001) or mild cases (p<0.05). D-dimer was also significantly higher in severe cases compared to moderate (p<0.001) or mild cases (p<0.01). LDH severe cases showed a significantly higher level compared to moderate cases (p<0.0001). Intriguinly, Albumin levels were not only significantly lower in severe cases compared to moderate disease (p<0.05) and mild cases (p<0.0001), but was also significantly lower in moderate disease compared to mild (p<0.01) (Figure 1).

Table 3

Mild (N) Moderate (N) Severe (N) N, X2,df P
Complication No complication 46 32 0 111,69.2,2 <.001
Complication 0 12 21
Outcome Recovery 46 44 8 111,63.1,2 <.001
In-patient mortality 0 0 13
Hx of Medical disease No medical condition 44 14 5 111,48.7,2 <.001
Medical condition 2 30 16
Gender Male 25 25 17 111,4.6,2 .098
Female 21 19 4
Age 18-44 32 16 2 110,27.2,4 <.001
45-64 11 20 11
≥ 65 2 8 8
Hgb Low 2 15 10 73,5.8,4 .214
Normal 6 28 10
High 1 0 1
RBC count Low 4 20 10 73,8.2,4 .084
Normal 5 23 8
High 0 0 3
PLT Low 0 7 6 73,5.4,4 .243
Normal 9 34 13
High 0 2 2
WBC Low 2 13 3 73,4.8,4 .300
Normal 7 25 13
High 0 5 5
Neutrophils Low 0 6 5 73,5.0,4 .283
Normal 8 27 10
High 1 10 6
Lymphocytes Low 9 36 18 73,1.6,2 .432
Normal 0 7 3
Monocytes Low 7 17 8 71,4.9,4 .292
Normal 1 20 9
High 1 5 3
Eosinophils Low 7 34 19 73,2.5,4 .630
Normal 2 7 1
High 0 2 1
Basophils Low 3 4 1 73,8.2,4 .084
Normal 5 35 20
High 1 4 0
D-Dimer Normal 5 12 5 59,2.5,2 .278
High 3 23 11
PT Normal 5 28 17 63,3.9,2 .141
High 1 11 1
APTT Normal 5 35 17 62,0.7,2 .686
High 1 3 1
INR Normal 6 28 16 63,3.9,2 .141
High 0 11 2
Ferritin Normal 2 10 3 58,0.4,2 .816
High 6 25 12
Na Low 3 19 11 73,0.9,2 .617
Normal 6 24 10
K Low 1 9 3 73,7.6,4 .104
Normal 8 32 13
High 0 2 5
Cl Low 1 3 5 73,3.7,2 .156
Normal 8 40 16
Urea Low 2 5 0 73,6.7,4 .152
Normal 6 25 11
High 1 13 10
Creatinine Low 2 7 3 72,3.3,4 .504
Normal 7 25 11
High 0 11 6
Total protein Low 0 2 2 70,2.3,4 .681
Normal 8 36 15
High 1 3 3
Albumin Low 4 27 17 70,6.6,2 <.036
Normal 5 15 2
ALP Normal 8 39 18 71,0.2,2 .888
High 1 3 2
AST Low 0 3 0 70,2.7,4 .601
Normal 3 15 9
High 6 24 10
ALT Normal 4 34 16 71,5.6,2 .059
High 5 8 4
GTT Normal 4 30 13 71,2.4,2 .297
High 5 12 7
Total Bilirubin Normal 8 37 19 71,0.7,2 .689
High 1 5 1
LDH Normal 1 5 3 59,0.1,2 .937
High 7 29 14

Demographic and laboratory parameters associated with COVID-19 severity.

Bold values indicate significant values.

Figure 1

Figure 1

Laboratory paramaters associated with disease severity. (A) Ferritin (B) D-dimer, (D) LDH levels increase with disease severity. (C) Albumin levels decreases with disease severity. Data presented as mean +/- SEM. * p value <0.05,** p <0.01,*** p <0.001,**** p <0.0001, ns indicates not significant (p>0.05).

Given that age and low albumin levels were two statistically significant categorical parameters associated with disease severity we wanted to study which would be more related to disease severity. Using GLM suggested that between the two significant factors age better predicts disease severity compared to albumin levels (Table 4). Age group 18-44 were expected to have a decrease in disease severity with a -0.419 [-0.821, -0.017] with a p=0.041.

Table 4

Parameter B S.E. 95% Confidence Interval p-value
Lower Bound Upper Bound
Age = 18-44 -0.419 0.201 -0.821 -0.017 0.041a
Age = 45-64 -0.057 0.180 -0.417 0.303 0.752
Albumin = Low 0.279 0.158 -0.037 0.595 0.083

Variables and Disease severity.

a-significant using General Linear Model at <0.05 level.

B= Logistic regression coefficient

S.E.= Standard error

Table 5 demonstrates the analysis of the various demographic and laboratory parameters categories in association with the disease outcome (inpatient mortality or recovery). As expected, there was a significant relationship between Covid complications and disease outcome X2 (1, N = 111) = 34.8, p <0.001. In addition, a history of previous medical conditions were associated with disease outcome X2 (1, N = 111) = 4.0, p =0.044. Although gender was not associated, age was significantly associated with disease outcome X2 (2, N = 110) = 12.8, p <0.01. Patients ≥ 65 and patients between 45-64 showed a significantly higher inpatients mortality compared to patients between 18-44 (p<0.001, p=0.026 respectively). No significant difference was seen though between patients ≥ 65 and patients between 45-64. Compellingly, out of all the measured laboratory parameters, only RBC count showed a significant relation with disease outcome X2 (2, N = 71) = 6.1, p =0.046. With further analysis of the continuous variables, we found that the same factors that were associated with disease severity were also associated with increased mortality (Figure 2). Significantly higher levels of LDH (p<0.001), D-dimer (p<0.0001), and ferritin (p<0.01), were found in in-patient mortality, while a significantly decreased level of Albumin (p<0.01) was seen in in-patient mortality. Other factors such as ALT or different types of white blood cells were not associated with patient recovery or mortality.

Table 5

Inpatient mortality Recovery N, X2, df P-value
Complication No complication 0 78 111,34.8,1 <.001
Complication 13 20
Hx of Medical disease No medical condition 4 59 111,4.0,1 <.044
Medical condition 9 39
Gender Male 9 58 111,0.4,1 .487
Female 4 40
Age 18-44 1 49 110,12.8,2 <.002
45-64 6 36
≥ 65 6 12
Hgb Low 6 21 73,2.2,2 .317
Normal 6 38
High 1 1
RBC count Low 7 27 71,6.1,2 <.046
Normal 4 32
High 2 1
PLT Low 1 12 73,1.1,2 .555
Normal 11 45
High 1 3
WBC Low 2 16 73,4,2 .131
Normal 7 38
High 4 6
Neutrophils Low 1 10 73,0.9,2 .621
Normal 8 37
High 4 13
Lymphocytes Low 11 52 73,0.0,1 .845
Normal 2 8
Monocytes Low 5 27 71,0.9,2 .615
Normal 7 23
High 1 8
Eosinophils Low 12 48 73,2.8,2 .240
Normal 0 10
High 1 2
Basophils Low 1 7 73,1.4,2 .488
Normal 12 48
High 0 5
D-Dimer Normal 3 19 59,0.5,1 .446
High 8 29
PT Normal 11 39 63,3.4,1 .063
High 0 13
APTT Normal 11 46 62,1.1,1 .279
High 0 5
INR Normal 11 39 63,3.4,1 .063
High 0 13
Ferritin Normal 2 13 58,0.0,1 .786
High 7 36
Na Low 4 29 73,1.3,1 .249
Normal 9 31
K Low 2 11 73,0.6,2 .729
Normal 9 44
High 2 5
Cl Low 1 8 73,0.3,1 .575
Normal 12 52
Urea Low 0 7 73,2.4,2 .301
Normal 7 35
High 6 18
Creatinine Low 3 9 72,1.9,2 .375
Normal 5 38
High 4 13
Total protein Low 1 3 70,0.2,2 .681
Normal 10 49
High 1 6
Albumin Low 10 38 70,1.4,1 .226
Normal 2 20
ALP Normal 11 54 71,0.0,1 .987
High 1 5
AST Low 0 3 70,0.6,2 .719
Normal 5 22
High 7 33
ALT Normal 9 45 71,0.0,1 .925
High 3 14
GTT Normal 9 38 71,0.5,1 .479
High 3 21
Total Bilirubin Normal 11 53 71,0.0,1 .846
High 1 6
LDH Normal 1 8 59,0.2,1 .612
High 9 41

Demographic and laboratory parameters associated with COVID-19 outcome.

Bold values indicate significant values.

Figure 2

Figure 2

Laboratory paramters association with patients’ outcomes. The level of different white blood cells did not change with patients’ outcomes (A). lymphocyte, (B) moncyte (C) eosinophil. On the other hand (D) D-dimer, (E) LDH, and (G) Ferrtin levels were all significantly higher in in patient mortality. (F) ALT levels were not effected by patients’ ouctome, while (H) Albumin levels were significantly decreased in patient mortality. Data presented as mean +/- SEM. ** p <0.01,*** p <0.001,**** p <0.0001, ns indicates not significant (p>0.05).

Using BLRM we found that when using age, disease severity, RBC count as variables, disease severity was the top predictor of disease outcome, followed by age, and RBC count (Table 6).

Table 6

Variables in the Equation B S.E. Exp(B) 95% C.I.for Exp(B) p-value
Lower Upper
Age 0.719
Age(18-44) 0.956 1.667 2.601 0.099 68.292 0.566
Age(45-64) 0.791 1.049 2.206 0.282 17.227 0.451
RBC count 0.785
RBC(Low) -0.048 1.453 0.953 0.055 16.428 0.974
RBC(Normal) 0.628 1.447 1.873 0.110 31.956 0.665
Disease severity >0.999
Disease severity(Mild) 21.437 13155.737 2.042E+09 0.000 0.999
Disease severity(Moderate) 21.564 6017.472 2.317E+09 0.000 0.997
Constant -1.246 1.460 0.288 0.394

Variables and Disease outcome.

Discussion

This study reflected on the experience of one of the largest educational hospitals in Saudi Arabia, KAUH, to define the laboratory markers used and associated with COVID-19 severity and outcome. In our study, age, low albumin levels, high ferritin, D-dimer and LDH were significantly associated with disease severity and outcome. In addition, normal RBC count appeared as an important parameter for patient’s outcome.

In our study, 62.7% of all patients showed high levels of D-dimer. D-dimer has beenassociated with COVID-19 and the disease severity (9–11). In a study of 248 COVID patients in Wuhuan, D-dimer was elevated in 74.6% of patients (11). Levels also increased with disease severity (10, 11) and higher levels on admission were found to predict mortality in a few studies (10). In a Saudi study, higher D-dimer levels were also found in mild to moderate disease (8). D-dimer is a degradation product of fibrin which is regularly used for diagnosis of thrombotic disorders. Various pathological and non-pathological conditions are expected to increase fibrin production and breakdown, including venous thromboembolism, disseminated intravascular coagulation, liver diseases, pregnancy, and inflammatory process. However, infection has been one of the most frequent reasons behind elevated D-dimer in admitted patients (12). It is thought that both the acute lung injury and the thromboemobolitic dysregulation seen in COVID-19 are the cause of the elevated D-dimer (9).

The majority of patients in our study (74%) showed high levels of serum ferritin. Levels were also significantly higher in severe disease and in patient mortality. Serum ferritin is known as an acute phase reactant which acts as an important inflammatory marker. Hyperferrtinemia has been demonstrated in a range of diseases including rheumatoid disorders, cancer and others, indicating the activation of the macrophage-monocyte system. Given the systemic inflammatory feature of COVID-19, hyperferrtinemia has been associated with the disease severity in several studies including Saudi Arabia (8, 13, 14). In two metanalysis studies, high serum ferritin was significantly increased in severe patients compared with non-severe patients, and in non-survivors compared with survivors (13, 14). In addition, patients who required ICU admission had higher levels than those who did not require ICU or mechanical ventilation (14). However, it is worth noting that a high heterogeneity was seen between studies, which according to authors could be contributed to differences in mean age and concomitant co-morbidities seen in patients, both of which are expected to effect serum ferritin levels (14).

LDH was also associated with disease severity and in inpatient mortality. LDH is an intracellular enzyme which is mostly active in the lungs, heart, liver and skeletal muscles. Increased blood concentration is seen in tissue damage and cell death and is though to be an important marker for lung damage (15, 16). Several studies and meta-analysis studies have shown that the enzyme was associated with disease severity and was found in higher levels in ICU patients and non-survival patients (15, 16). In severe cases, LDH together with ferritin were found to be prognostic for ARDS development (17).

In this study, low albumin levels were found in the majority of patients. In addition, severe cases and patient morality showed significantly lower levels. Noteworthy, as a category, low albumin levels appeared to be the only laboratory parameter that was significantly associated with disease severity. Low serum albumin has been associated with disease severity in other studies (18–20). In a meta analysis study analyzing sixty-seven studies with a total of 19,760 COVID-19 patients, it was concluded that low albumin concentration were significantly lower in patients with severe disease (18). In addition, albumin was shown to be an independent risk for mortality (21, 22). It is known that albumin is a crucial protein that exerts homeostatic functions, and is the most essential protein for inducing oncotic pressure in the vascular system. Various reasons have been suggested to explain the hypoalbuminemia seen in severe cases of Covid-19. For example, impaired liver synthesis, or albumin loss by the kidney can be expected in severe cases, yet, this is not usually the case and indeed this was not reflected in the liver and kidney function biomarkers in our study. Reason explaining the low albumin concentration could be related to the characteristic inflammatory state of COVID-19, which due to vascular permeability could result in the extravasation of serum albumin into the interstitial fluid (18). Even so, it is also important to recognize that albumin concentrations tend to decrease with age, and given that age is associated with COVID disease severity, the relationship with albumin could be a secondary association. Emphasizing the importance of albumin, a recent retrospective study on 114 COVID-19 patients have demonstrated that albumin infusion to ICU patients with hypoalbuminemia was associated with shorter hospitalization, prolonged survival, and enhancement in some of the laboratory markers (23).

Interestingly in this study, normal and low levels of RBCs were associated with disease recovery. RBCs are responsible for oxygen transport from lungs to tissue. Despite this, their role as passive carriers has been challenged in the last decades (24, 25). Their processing and delivery of vasoactive factors such as NO is thought to result in vasoregulation that can caliber blood vessels and therefore regulate blood flow based on oxygen availability in the lung and consumption in the periphery (24). Another active role for RBC was further demonstrated when abnormalities in RBCs numbers and function was found to be associated with both arterial and venous thrombosis (25). For example, the risk of CVD is found to be two-fold greater in high hematocrit patients vs low hematocrit, in addition 20% of polycythemia patients present with thrombosis as their main symptom (25). This could be explained by RBCs being a primary factor in blood viscosity, and it is known that an increased blood viscosity is a main risk factor for thrombosis. A normal to low RBC count perhaps acts as a protective factor from developing a thrombotic event in COVID-19 patients, which might explain why normal and low RBC counts were associated with recovery from disease in our study. However, further larger studies would be required to investigate the impact of RBC counts and function in COVID-19 severity.

RBC are constantly exposed to endogenous and exogenous reactive oxygen species which require an anti-oxidant system to neutralize such excess ROS. Failure or overwhelming this anti-oxidant system can result in RBC aging, structure damage, and thus stimulates clearance of those RBCs. Given the high ROS production in COVID-19 which is thought to be generated from neutrophils (26), an RBC clearance due to oxidative stress might explain the low RBCs seen with COVID-19 in some studies.

Several studies have showed that age is related to disease severity and outcome (27, 28). In a meta-analysis study on 36,470 patients from 59 studies, men, and patients over 70 had a higher risk for severe disease, ICU admission, and death (27). Ageing is obviously associated with more co-morbidities, and a decrease in immune and organ function, all of which is expected to increase mortality risk. In our study, age was significantly associated with disease severity and disease outcome, and using a linear regression model, being in the younger age group (18-44) was a more significant factor than albumin levels in predicting a milder disease. Interestingly, unlike other studies gender was not significantly associated with disease severity or disease outcome in our study. Several factors are thought to contribute to sex dependent difference including hormonal, behavioral such as smoking, immunological, and anatomical such as distribution of the angiotensin-converting enzyme 2 (ACE-2) receptors (29). It would be interesting therefore to study these differences in more depth in the Saudi population, and to study whether some specific factors such as the increasing smoking prevalence among the Saudi females, or other genetic factors might mask sex-dependent covid outcome in the Saudi population. However, it is worth noting that a study with a larger sample size would be required to further confirm the results.

Overall, this study aids in discovering predictive factors to COVID-19 severity and outcome in KAUH which was previously deficient, specifically at the time the study was conducted when admission criteria guidelines were set following the initial phase of the disease. However, we acknowledge that the small sample size and being a single center study is a limitation in our study. In addition, the study is a retrospective study which implies that some variables and data that would have given more information to the study were not available, including information that could have classified patients further according to the WHO ordinal severity scale. Furthermore, the lack of control group, for example patients with other respiratory infections, precludes discussion on whether the markers observed are to be increased or decreased in severe COVID-19 are specific to COVID-19 or apply to patients with severe respiratory infections in general.

Laboratory tests are overall, simple, non-invasive, accessible, and can be repeatedly ordered, which makes them attractive for the use in machine learning (ML) models that can contribute in the diagnosis or prognosis of COVID-19. Indeed, despite that early COVID-19 ML models were mainly based on radiographic data, more laboratory based ML models followed after that (30).

Identifying the laboratory markers to be used in diagnostic or prognostic ML models is of crucial importance. For example, markers that are expensive, not routinely available, cannot be ordered fast, or that have a long analytical time would be non-applicable (30). In addition, the markers needs to be of diagnostic value in the relevant population. In a recent systematic review, sixty-eight articles have been identified for using laboratory data only ML models in the diagnosis or prognosis of COVID-19, however, none of those studies were conducted in the Saudi population (30).

We believe that our study aided in predicting parameters that are relevant to the Saudi population and which can together with data from other Saudi studies help build ML models that can enhance patient management.

Statements

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

This study was a retrospective study conducted at KAUH in Jeddah, Saudi Arabia and approved by the Biomedical Research Ethics Committee ethics board at King Abdul-Aziz University (Reference No 360-20).

Author contributions

The Conceptualization: AA, SE, BE, GA. Data curation: AA, SE. Formal analysis: AA, SE, HB, SA. Writing – review & editing: AA, BE, GA, RB, MB, AE. All authors read and approved the final manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    Ciotti M Ciccozzi M Terrinoni A Jiang W-C Wang C-B Bernardini S . The COVID-19 pandemic. Crit Rev Clin Lab Sci (2020) 57(6):365–88. doi: 10.1080/10408363.2020.1783198

  • 2

    Novelli G Biancolella M Mehrian-Shai R Erickson C Godri Pollitt KJ Vasiliou V et al . COVID-19 update: the first 6 months of the pandemic. Hum Genomics (2020) 14(1):48. doi: 10.1186/s40246-020-00298-w

  • 3

    Dashboard WC . (2020). Geneva: World Health Organization. Available at: https://covid19.who.int/.

  • 4

    Bivona G Agnello L Ciaccio M . Biomarkers for prognosis and treatment response in COVID-19 patients. Ann Lab Med (2021) 41(6):540–8. doi: 10.3343/alm.2021.41.6.540

  • 5

    Nasserie T Hittle M Goodman SN . Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open (2021) 4(5):e2111417. doi: 10.1001/jamanetworkopen.2021.11417

  • 6

    Alqahtani F Khan A Alowais J Alaama T Jokhdar H . Bed surge capacity in Saudi hospitals during the COVID-19 pandemic. Disaster Med Public Health Prep (2021) p. 1–7. doi: 10.1017/dmp.2021.117

  • 7

    Ibrahim ME Al-Aklobi OS Abomughaid MM Al-Ghamdi MA . Epidemiological, clinical, and laboratory findings for patients of different age groups with confirmed coronavirus disease 2019 (COVID-19) in a hospital in Saudi Arabia. PLoS One (2021) 16(4):e0250955. doi: 10.1371/journal.pone.0250955

  • 8

    Al Mutair A Alhumaid S Alhuqbani WN Zaidi ARZ Alkoraisi S Al-Subaie MF et al . Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: an observational cohort study. Eur J Med Res (2020) 25(1):61. doi: 10.1186/s40001-020-00462-x

  • 9

    Lehmann A Prosch H Zehetmayer S Gysan MR Bernitzky D Vonbank K et al . Impact of persistent d-dimer elevation following recovery from COVID-19. PLoS One (2021) 16(10):e0258351. doi: 10.1183/13993003.congress-2021.OA90

  • 10

    Poudel A Poudel Y Adhikari A Aryal BB Dangol D Bajracharya T et al . D-dimer as a biomarker for assessment of COVID-19 prognosis: d-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One (2021) 16(8):e0256744. doi: 10.1371/journal.pone.0256744

  • 11

    Yao Y Cao J Wang Q Shi Q Liu K Luo Z et al . D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care (2020) 8:49. doi: 10.1186/s40560-020-00466-z

  • 12

    Lippi G Bonfanti L Saccenti C Cervellin G . Causes of elevated d-dimer in patients admitted to a large urban emergency department. Eur J Intern Med (2014) 25(1):45–8. doi: 10.1016/j.ejim.2013.07.012

  • 13

    Cheng L Li H Li L Liu C Yan S Chen H et al . Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal (2020) 34(10):e23618. doi: 10.1002/jcla.23618

  • 14

    Kaushal K Kaur H Sarma P Bhattacharyya A Sharma DJ Prajapat M et al . Serum ferritin as a predictive biomarker in COVID-19. a systematic review, meta-analysis and meta-regression analysis. J Crit Care (2022) 67:172–81. doi: 10.1016/j.jcrc.2021.09.023

  • 15

    Fialek B Pruc M Smereka J Jas R Rahnama-Hezavah M Denegri A et al . Diagnostic value of lactate dehydrogenase in COVID-19: a systematic review and meta-analysis. Cardiol J (2022) 29(5):751–8. doi: 10.5603/CJ.a2022.0056

  • 16

    Henry BM Aggarwal G Wong J Benoit S Vikse J Plebani M et al . Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med (2020) 38(9):1722–6. doi: 10.1016/j.ajem.2020.05.073

  • 17

    Martinez Mesa A Cabrera César E Martín-Montañez E Sanchez Alvarez E Lopez PM Romero-Zerbo Y et al . Acute lung injury biomarkers in the prediction of COVID-19 severity: total thiol, ferritin and lactate dehydrogenase. Antioxidants (Basel) (2021) 10(8):1221. doi: 10.3390/antiox10081221

  • 18

    Paliogiannis P Mangoni AA Cangemi M Fois AG Carru C Zinellu A . Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis. Clin Exp Med (2021) 21(3):343–54. doi: 10.1007/s10238-021-00686-z

  • 19

    Parohan M Yaghoubi S Seraji A . Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies. Hepatol Res (2020) 50(8):924–35. doi: 10.1111/hepr.13510

  • 20

    Wang Y Shi L Wang Y Duan G Yang H . Albumin and total bilirubin for severity and mortality in coronavirus disease 2019 patients. J Clin Lab Anal (2020) 34(7):e23412. doi: 10.1002/jcla.23412

  • 21

    Violi F Cangemi R Romiti GF Ceccarelli G Oliva A Alessandri F et al . Is albumin predictor of mortality in COVID-19? Antioxid Redox Signal (2021) 35(2):139–42. doi: 10.1089/ars.2020.8142

  • 22

    Zerbato V Sanson G De Luca M Di Bella S di Masi A Caironi P et al . The impact of serum albumin levels on COVID-19 mortality. Infect Dis Rep (2022) 14(3):278–86. doi: 10.3390/idr14030034

  • 23

    Zhang L Yu W Zhao Y Chen X Wang P Fan X et al . Albumin infusion may improve the prognosis of critical COVID-19 patients with hypoalbuminemia in the intensive care unit: a retrospective cohort study. Infect Drug Resist (2022) 15:6039–50. doi: 10.2147/IDR.S383818

  • 24

    Rogers S Doctor A . Red blood cell dysfunction in critical illness. Crit Care Clin (2020) 36(2):267–92. doi: 10.1016/j.ccc.2019.12.008

  • 25

    Byrnes JR Wolberg AS . Red blood cells in thrombosis. Blood (2017) 130(16):1795–9. doi: 10.1182/blood-2017-03-745349

  • 26

    Veenith T Martin H Le Breuilly M Whitehouse T Gao-Smith F Duggal N et al . High generation of reactive oxygen species from neutrophils in patients with severe COVID-19. Sci Rep (2022) 12(1):10484. doi: 10.1038/s41598-022-13825-7

  • 27

    Pijls BG Jolani S Atherley A Derckx RT Dijkstra JIR Franssen GHL et al . Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open (2021) 11(1):e044640. doi: 10.1136/bmjopen-2020-044640

  • 28

    Zhang JJ Dong X Liu GH Gao YD . Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol (2023) 64(1):90–107. doi: 10.1007/s12016-022-08921-5

  • 29

    Ancochea J Izquierdo JL Soriano JB . Evidence of gender differences in the diagnosis and management of coronavirus disease 2019 patients: an analysis of electronic health records using natural language processing and machine learning. J Womens Health (Larchmt) (2021) 30(3):393–404. doi: 10.1089/jwh.2020.8721

  • 30

    Carobene A Milella F Famiglini L Cabitza F . How is test laboratory data used and characterised by machine learning models? a systematic review of diagnostic and prognostic models developed for COVID-19 patients using only laboratory data. Clin Chem Lab Med (2022) 60(12):1887–901. doi: 10.1515/cclm-2022-0182

Summary

Keywords

laboratory parameters, Covid-19, disease severity, outcome, King Abdulaziz University Hospital (KAUH), albumin

Citation

Alamoudi AA, Eldakhakhny S, Banjar H, Ajabnoor G, Aljohani SB, Basheer RR, Eldakhakhny B, Badawi M and Elsamanoudy A (2023) Association between laboratory markers and Covid-19 disease severity and outcome: a retrospective cohort study in Saudi Arabia. Front. Immunol. 14:1198530. doi: 10.3389/fimmu.2023.1198530

Received

01 April 2023

Accepted

26 June 2023

Published

11 July 2023

Volume

14 - 2023

Edited by

Soheil Ebrahimpour, Babol University of Medical Sciences, Iran

Reviewed by

Caitlin Pley, Charité University Medicine Berlin, Germany; Erkan Cüre, Beylikduzu Medilife Hospital, Türkiye

Updates

Copyright

© 2023 Alamoudi, Eldakhakhny, Banjar, Ajabnoor, Aljohani, Basheer, Eldakhakhny, Badawi and Elsamanoudy.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Rasha Ramadan Basheer,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics